---
---

# 21 U.S.C., USLM ref /us/usc/t21/s360n

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s360m.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s360n–1.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs360n)

## § 360n. Priority review to encourage treatments for tropical diseases

    (a) __Definitions__ 

    In this section:

        (1) __Priority review__ 

            The term “priority review”, with respect to a human drug application as defined in [section 379g(1) of this title][/us/usc/t21/s379g/1], means review and action by the Secretary on such application not later than 6 months after receipt by the Secretary of such application, as described in the Manual of Policies and Procedures of the Food and Drug Administration and goals identified in the letters described in section 101(c) of the Food and Drug Administration Amendments Act of 2007.

        (2) __Priority review voucher__ 

            The term “priority review voucher” means a voucher issued by the Secretary to the sponsor of a tropical disease product application that entitles the holder of such voucher to priority review of a single human drug application submitted under [section 355(b)(1) of this title][/us/usc/t21/s355/b/1] or [section 262 of title 42][/us/usc/t42/s262] after the date of approval of the tropical disease product application.

        (3) __Tropical disease__ 

        The term “tropical disease” means any of the following:

            (A) Tuberculosis.

            (B) Malaria.

            (C) Blinding trachoma.

            (D) Buruli Ulcer.

            (E) Cholera.

            (F) Dengue/dengue haemorrhagic fever.

            (G) Dracunculiasis (guinea-worm disease).

            (H) Fascioliasis.

            (I) Human African trypanosomiasis.

            (J) Leishmaniasis.

            (K) Leprosy.

            (L) Lymphatic filariasis.

            (M) Onchocerciasis.

            (N) Schistosomiasis.

            (O) Soil transmitted helmithiasis.

            (P) Yaws.

            (Q) Filoviruses.

            (R) Any other infectious disease for which there is no significant market in developed nations and that disproportionately affects poor and marginalized populations, designated by order of the Secretary.

        (4) __Tropical disease product application__ 

        The term “tropical disease product application” means an application that—

            (A)

             is a human drug application as defined in [section 379g(1) of this title][/us/usc/t21/s379g/1]—

                (i) for prevention or treatment of a tropical disease; and

                (ii) the Secretary deems eligible for priority review;

            (B) is approved after September 27, 2007, by the Secretary for use in the prevention, detection, or treatment of a tropical disease; and

            (C) is for a human drug, no active ingredient (including any ester or salt of the active ingredient) of which has been approved in any other application under [section 355(b)(1) of this title][/us/usc/t21/s355/b/1] or [section 262 of title 42][/us/usc/t42/s262].

    (b) __Priority review voucher__ 

        (1) __In general__ 

            The Secretary shall award a priority review voucher to the sponsor of a tropical disease product application upon approval by the Secretary of such tropical disease product application.

        (2) __Transferability__ 

            The sponsor of a tropical disease product that receives a priority review voucher under this section may transfer (including by sale) the entitlement to such voucher to a sponsor of a human drug for which an application under [section 355(b)(1) of this title][/us/usc/t21/s355/b/1] or [section 262 of title 42][/us/usc/t42/s262] will be submitted after the date of the approval of the tropical disease product application. There is no limit on the number of times a priority review voucher may be transferred before such voucher is used.

        (3) __Limitation__ 

            (A) __No award for prior approved application__ 

                A sponsor of a tropical disease product may not receive a priority review voucher under this section if the tropical disease product application was submitted to the Secretary prior to September 27, 2007.

            (B) __One-year waiting period__ 

                The Secretary shall issue a priority review voucher to the sponsor of a tropical disease product no earlier than the date that is 1 year after September 27, 2007.

        (4) __Notification__ 

            The sponsor of a human drug application shall notify the Secretary not later than 90 days prior to submission of the human drug application that is the subject of a priority review voucher of an intent to submit the human drug application, including the date on which the sponsor intends to submit the application. Such notification shall be a legally binding commitment to pay for the user fee to be assessed in accordance with this section.

    (c) __Priority review user fee__ 

        (1) __In general__ 

            The Secretary shall establish a user fee program under which a sponsor of a human drug application that is the subject of a priority review voucher shall pay to the Secretary a fee determined under paragraph (2). Such fee shall be in addition to any fee required to be submitted by the sponsor under subchapter VII.

        (2) __Fee amount__ 

            The amount of the priority review user fee shall be determined each fiscal year by the Secretary and based on the average cost incurred by the agency in the review of a human drug application subject to priority review in the previous fiscal year.

        (3) __Annual fee setting__ 

            The Secretary shall establish, before the beginning of each fiscal year beginning after September 30, 2007, for that fiscal year, the amount of the priority review user fee.

        (4) __Payment__ 

            (A) __In general__ 

                The priority review user fee required by this subsection shall be due upon the submission of a human drug application under [section 355(b)(1) of this title][/us/usc/t21/s355/b/1] or [section 262 of title 42][/us/usc/t42/s262] for which the priority review voucher is used.

            (B) __Complete application__ 

                An application described under subparagraph (A) for which the sponsor requests the use of a priority review voucher shall be considered incomplete if the fee required by this subsection and all other applicable user fees are not paid in accordance with the Secretary’s procedures for paying such fees.

            (C) __No waivers, exemptions, reductions, or refunds__ 

                The Secretary may not grant a waiver, exemption, reduction, or refund of any fees due and payable under this section.

        (5) __Offsetting collections__ 

        Fees collected pursuant to this subsection for any fiscal year—

            (A) shall be deposited and credited as offsetting collections to the account providing appropriations to the Food and Drug Administration; and

            (B) shall not be collected for any fiscal year except to the extent provided in advance in appropriation Acts.

([June 25, 1938, ch. 675][/us/act/1938-06-25/ch675], § 524, as added [Pub. L. 110–85, title XI][/us/pl/110/85/tXI], § 1102, Sept. 27, 2007, [121 Stat. 972][/us/stat/121/972]; amended [Pub. L. 113–233][/us/pl/113/233], § 2, Dec. 16, 2014, [128 Stat. 2127][/us/stat/128/2127].)

 __References in Text__ 

    Section 101(c) of the Food and Drug Administration Amendments Act of 2007, referred to in subsec. (a)(1), is [section 101(c) of Pub. L. 110–85][/us/pl/110/85/s101/c], which is set out as a note under [section 379g of this title][/us/usc/t21/s379g].

 __Amendments__ 

    2014—Subsec. (a)(3)(Q), (R). [Pub. L. 113–233][/us/pl/113/233], § 2(1), added subpar. (Q), redesignated former subpar. (Q) as (R), and in subpar. (R) substituted “order of” for “regulation by”.

    Subsec. (b)(2). [Pub. L. 113–233][/us/pl/113/233], § 2(2)(A), inserted at end “There is no limit on the number of times a priority review voucher may be transferred before such voucher is used.”

    Subsec. (b)(4). [Pub. L. 113–233][/us/pl/113/233], § 2(2)(B), substituted “90 days” for “365 days”.

----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s360m.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s360n–1.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs360n)

----------
----------

[/us/usc/t21/s379g/1]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs379g%2F1
[/us/usc/t21/s355/b/1]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355%2Fb%2F1
[/us/usc/t42/s262]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs262
[/us/usc/t21/s379g/1]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs379g%2F1
[/us/usc/t21/s355/b/1]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355%2Fb%2F1
[/us/usc/t42/s262]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs262
[/us/usc/t21/s355/b/1]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355%2Fb%2F1
[/us/usc/t42/s262]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs262
[/us/usc/t21/s355/b/1]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355%2Fb%2F1
[/us/usc/t42/s262]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs262
[/us/act/1938-06-25/ch675]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fact%2F1938-06-25%2Fch675
[/us/pl/110/85/tXI]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F110%2F85%2FtXI
[/us/stat/121/972]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F121%2F972
[/us/pl/113/233]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F113%2F233
[/us/stat/128/2127]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F128%2F2127
[/us/pl/110/85/s101/c]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F110%2F85%2Fs101%2Fc
[/us/usc/t21/s379g]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs379g
[/us/pl/113/233]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F113%2F233
[/us/pl/113/233]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F113%2F233
[/us/pl/113/233]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F113%2F233


